



O P E  
Please type a plus sign (+) inside this box → [+]

JAN 07 2004

C56

PATENT & TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 3

### COMPLETE IF KNOWN

Application Number	10/649,852
Confirmation Number	7224
Filing Date	August 27, 2003
First Named Inventor	Robert J. Isfort
Group Art Unit	
Examiner Name	
Attorney Docket Number	8448R

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
AKS	9	T.M. REYES, ET AL., "Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors", <i>PNAS</i> , February 27, 2001, 2843-2848, Vol. 98, No. 5, USA.	
GHS	10	E.B. DE SOUZA, "Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role In Central Nervous System and Immune Disorders", <i>Psychoneuroendocrinology</i> , 1995, 789-819, Vol. 20, No. 8, Elsevier Science Ltd., USA.	
GHS	11	D.T. CHALMERS, ET AL., "Corticotropin-releasing factor receptors: from molecular biology to drug design", <i>TiPS</i> , April 1996, 166-172, Vol. 17, Elsevier Science Ltd., USA	
	12	H.A. THOMAS, ET AL., "CRF and Related Peptides as Anti-Inflammatory Agents", <i>Annals New York Academy of Sciences</i> , 219-228, VOL V, Year ?	
GHS	13	E.T. WEI, ET AL., "Peripheral anti-inflammatory actions of corticotropin-releasing factor", <i>Ciba Foundation Symposium 172</i> , 1993, 258-276, Wiley, Chichester.	
AKS	14	J.R. MCCARTHY, ET AL., "Recent Advances with the CRF <sub>1</sub> Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications", <i>Current Pharmaceutical Design</i> , 1999, 289-315, Vol. 5, Bentham Science Publishers B.V.	
	15	J.R. MCCARTHY, ET AL., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents", <i>Annual Reports in Medicinal Chemistry</i> , 11-20, Vol. 34, Academic Press, Year ?	
AKS	16	G.P. CROUSOS, ET AL., "Corticotropin Releasing Factor: Basic Studies and Clinical Applications", <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> , 1985, 349-359, Vol. 9, Pergamon Press Ltd., Great Britain.	
GHS	17	G.B. CUTLER, JR., M.D., "Corticotropin-Releasing Hormone (CRH): Clinical Studies and Use", <i>The Endocrinologist</i> , 1997, 10S-16S, Vol. 7, No. 1, Suppl. 1, Williams & Wilkins.	
GHS	18	M.J. OWENS, ET AL., "Physiology and Pharmacology of Corticotropin-releasing Factor", <i>Pharmacological Reviews</i> , 1991, 425-473, Vol. 43, No. 4, The American Society for Pharmacology and Experimental Therapeutics, USA.	
AKS	19	L. ARBORELIUS, ET AL., "The role of corticotropin-releasing factor in depression and anxiety disorders", <i>Journal of Endocrinology</i> , 1999, 1-12, Vol. 160, Society for Endocrinology, Great Britain.	
AKS	20	D.N. ORTH, "Corticotropin-Releasing Hormone in Humans", <i>Endocrine Reviews</i> , 1992, 164-191, Vol. 13, No. 2, The Endocrine Society, USA.	
GHS	21	E. EMERIC-SAUVAL, "Corticotropin-Releasing Factor (CRF) - A Review", <i>Psychoneuroendocrinology</i> , 1985, 277-294, Vol. 11, No. 3, Pergamon Journals Ltd., Great Britain.	
AKS	22	J. SPIESS, ET AL., "Molecular Properties of the CRF Receptor", <i>TEM</i> , 1998, 140-145, Vol. 9, No. 4, Elsevier Science Ltd.	
GHS	23	K.D. DIETERICH, ET AL., "Corticotropin-releasing factor receptors: An overview", <i>Exp. Clin. Endocrinol. Diabetes</i> , 1997, 65-82, Vol. 105, Johann Ambrosius Barth.	
AKS	24	P.J. GILLIGAN, ET AL., "Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents", <i>Journal of Medicinal Chemistry</i> , May 4, 2000, 1641-1660, Vol. 43, No. 9, American Chemical Society.	
AKS	25	C.A. MALTIN, ET AL., "Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients", <i>Clinical Science</i> , 1993, 651-654, Vol. 84.	

QIP  
Please type plus sign (+) inside this box → [+]

JAN 07 2004

PTO/SB08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PATENT & TRADEMARK OFFICE  
Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	10/649,852
Confirmation Number	7224
Filing Date	August 27, 2003
First Named Inventor	Robert J. Isfort
Group Art Unit	
Examiner Name	
Attorney Docket Number	8448R

SHEET 3 of 3

44	26	J.F. SIGNORILE, ET AL., "Increased Muscle Strength in Paralyzed Patients after Spinal Cord Injury: Effect of Beta-2 Adrenergic Agonist", <i>Arch Phys Med Rehabil</i> , 1995, 55-58, Vol. 76.	
45	27	L. MARTINEAU, ET AL., "Salbutamol, a $\beta_2$ -adrenoceptor agonist, increases skeletal muscle strength in young men", <i>Clinical Science</i> , 1992, 615-621, Vol. 83.	
46	28	MEDLER, S., "Comparative trends in shortening velocity and force production in skeletal muscles", <i>Am. J. Physiol Regulatory Integrative Comp Physiol</i> , 2002, Vol. 283, pp. R368-R378.	
47	29	ROME, L.C., "The Design of Vertebrate Muscular Systems: Comparative and Integrative Approaches", <i>Clinical Orthopaedics and Related Research</i> , 2002, No. 403S, pp. S59-S76.	

EXAMINER

Shelomith H. Shafet

DATE CONSIDERED

9-22-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.